Chris Packard, United Kingdom
University of Glasgow Institute of Cardiovascular and Medical SciencesChris J Packard CBE BSc, PhD, DSc FRCPath, FRCP(Gla), FRSE.
Honorary Senior Research Fellow & Professor of Vascular Biochemistry,
University of Glasgow
Over 35 years of active scientific investigation Chris Packard has focussed on a number of aspects of atherosclerosis research including lipoprotein metabolism and how it is affected by diets and drugs, large-scale clinical trials of lipid lowering agents, emerging risk factors for coronary heart disease, and the impact of social deprivation on health. Key contributions on the kinetics of apolipoprotein B include evaluation of the role of the LDL receptor in vivo and how it is activated by lipid lowering drugs, the discovery of metabolic channelling in the VLDL-LDL delipidation cascade, and the formulation of models to explain the generation of small, dense LDL. Recent research has focussed on the role of triglyceride-rich lipoproteins in atherosclerosis, genetic determinants of dyslipidemia and pharmacological modulation of intestinal and liver derived lipoproteins.
As one of the main investigators of the West of Scotland Coronary Prevention Study (WOSCOPS) and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Chris Packard helped establish the evidence base for statin use in CHD prevention. These trials provided confidence that statins are beneficial in primary prevention and in older adults. Publication of the 20 year follow up of WOSCOPS (in 2016) not only provided unique long-term safety data but also established the advantages of using health informatics in pharmacovigilance. Work from his laboratory has helped elucidate the role of biomarkers such as troponin I, CRP and lipoprotein-associated phospholipase A2 in predicting risk of CHD.
Presenter of 3 Presentations
PCSK9 inhibition: what do we know so far?
Session Name
Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
14:30 - 16:00
Lecture Time
14:36 - 14:48
Presenter
Webcast
LIVE Panel discussion: with a focus on very-high risk patients
Session Name
Session Type
Industry Sponsored Session
Date
07.10.2020, Wednesday
Session Time
14:30 - 16:00
Lecture Time
15:28 - 15:53
Webcast
Targets and goals - The EAS way
Session Type
Joint symposium
Date
04.10.2020, Sunday
Session Time
14:30 - 15:30
Lecture Time
14:30 - 14:45
Presenter